Analyzing...
Loading company...
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹2,839 Cr revenue.
COGS 0.0%, employees 63.9%.
“grew revenue by 30.”
“we have very clearly laid down that in the next six to eight quarters, we will get our margins back to, the levels you were at.”
“EBITDA is expected to begin sequential improvement from quarter one of FY twenty seven.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 15.3%▲ | 10.5% |
| ROCE | 19.3%▲ | 13.8% |
| Net Margin | 13.1%▲ | 8.7% |
| EBITDA Margin | 20.6%▲ | 16.0% |
| Debt To Equity | 0.00x▼ | 0.21x |
Historical valuation data not available.
| (₹ Cr) | TTM | FY2025 | FY2024 |
|---|---|---|---|
| Revenue | ₹3,263 Cr +14.9% | ₹2,839 Cr +9.6% | ₹2,590 Cr |
| Other Income | ₹87 Cr -19.0% | ₹107 Cr +40.5% | ₹76 Cr |
| Total Income | ₹3,350 Cr +13.7% | ₹2,947 Cr +10.5% | ₹2,666 Cr |
| ₹2,780 Cr +15.5% | ₹2,407 Cr +8.9% | ₹2,210 Cr | |
| Profit Before Tax | ₹569 Cr +5.5% | ₹539 Cr +17.6% | ₹459 Cr |
| ₹130 Cr -1.8% | ₹133 Cr +8.8% | ₹122 Cr | |
| Net Profit | ₹439 Cr +7.9% | ₹407 Cr +20.8% | ₹337 Cr |
| Profit (Owners) | ₹439 Cr +7.9% | ₹407 Cr +20.8% | ₹337 Cr |
| Other Comprehensive Income | ₹87 Cr +239.8% | ₹26 Cr +224.1% | ₹8 Cr |
| EPS | ₹18.28 | ₹16.95 | ₹14.07 |
| Diluted Shares | ₹24 Cr | ₹24 Cr | ₹24 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Indegene Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, ...
Indegene Limited has informed the Exchange about Schedule of meet
Indegene Limited has informed the Exchange about Presentation
Indegene Limited has informed the Exchange about Link of Recording
Indegene Limited has informed the Exchange about Schedule of meet
Indegene Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Indegene Limited has informed the Exchange about Schedule of meet
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Indegene Limited has informed the Exchange regarding Allotment of 327880 Shares.
Indegene Limited has informed the Exchange about Schedule of meet
Intimation of Schedule of Investors / Analysts meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015
Transcript of the earnings conference call on financial results for the quarter ended December 31, 2025
Indegene Limited has informed the Exchange about Copy of Newspaper Publication
Indegene Limited has informed the Exchange about Link of Recording
Indegene Limited has informed the Exchange about Intimation of opening of trading window.